Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Adherence news


From To
Is the World Ready for Long-Acting HIV Treatment?

"As we look at this question [of] where do long-acting antiretrovirals fit into the armamentarium," commented Carl Dieffenbach, the director of the Division of AIDS within the National Institute of Allergy and Infectious Diseases, "we have to ask ourselves the question: What problems are long-acting or sustained-release formulations solving, and what problems or concerns are the introduction of these type of formulations actually creating?"

11 June 2018
The Body Pro
Short Cycle ART Noninferior to Continuous Therapy in Youth With HIV

Short cycle therapy (SCT) comprising an antiretroviral therapy (ART) regime of 5 days on and 2 off achieved sustainable noninferiority of virological suppression in young people with HIV compared with continuous therapy (CT) over a median of 3.6 years, according to research published in PLos One.

25 May 2018
Infectious Disease Advisor
Smartphone app keeps an 'eye' on daily tuberculosis therapy

Johns Hopkins researchers report success with a smart phone video-based app that substitutes for a daily in-person visit by a health care worker required for tuberculosis treatment known as directly observed therapy, or DOT. The preliminary study showed that the app may be less costly and may improve privacy concerns raised by patients compared to in-person visits.

27 April 2018
Eurekalert Inf Dis
Has Anyone Gotten HIV When They Were on PrEP?

At least 300,000 individuals are now using PrEP worldwide, and only two incidents have been reported where individuals with verified adherence to the drug acquired HIV. Three additional cases have been reported with unconfirmed adherence, and three are currently under investigation.

22 April 2018
The Body
Uganda:HIV Patients to Get Rewards for Taking ARVs

Mildmay Uganda and the United States based RAND Corporation yesterday launched a five-year research study of rewarding people living with HIV who take their antiretroviral drugs consistently.

20 April 2018
Researchers ID four types of nonbiomedical PrEP failure

Serota and colleagues describe 14 men who became infected with HIV in their EleMENt study of 300 young BMSM in Atlanta, despite being offered PrEP, along with services to ease access to PrEP uptake. They rightly point out that, in addition to the rare biomedical PrEP failures that receive so much attention at scientific meetings, we should focus our attention on the other “typologies” of PrEP failure that occur once PrEP is offered: low PrEP adherence, PrEP discontinuation, PrEP contemplation without initiation and PrEP refusal.

14 April 2018
ARV stock-outs kill more Ugandans

“Of recent, HIV drug stock-out is adding a lot of misery to us as service providers in the ART clinics because we get very few drugs from National Medical Stores (NMS) which is not enough for our patients. We keep on begging for drugs from nearby health centres. When patients spend long time without taking drugs, they develop resistance,” Dr Peter Andrew Kalema said.

12 April 2018
The Observer
Violence a major driver for teens not taking their HIV treatment

Four types of violence were independently associated with adherence – physical abuse by caregivers; witnessing domestic violence; teacher violence; or verbal victimisation by healthcare staff. The researchers comment that violence and victimisation from these sources “evoke a sense of betrayal among adolescents for whom they are hoped-for sources of care and support."

06 April 2018
Antiretroviral drug levels in hair strongly predict viral suppression

Antiretroviral drug levels in a sample of hair were the strongest predictor of response to HIV treatment, and this method also holds promise for monitoring adherence to pre-exposure

06 March 2018
Liz Highleyman
Zambia: HIV deaths on treatment underestimated

People with HIV in Zambia were at least ten times more likely to die in the first two years after starting antiretroviral treatment than European

14 February 2018
Keith Alcorn

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.